Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
BACKGROUND
Empirical antifungal therapy is the standard treatment for persistent or relapsing antibiotic-resistant neutropenic fever. However, overtreatment resulting in increased toxicity and treatment-related cost is a major shortcoming of such therapy. We assessed the feasibility of a "preemptive" approach based on the incorporation of sensitive, noninvasive diagnostic tests for consecutive high-risk neutropenic patients who had received fluconazole prophylaxis while avoiding empirical therapy.


METHODS
A total of 136 treatment episodes for persons who were at risk of acquiring invasive fungal infection (IFI) were screened for the presence of galactomannan with an enzyme immunoassay. A diagnostic evaluation, which included thoracic computed tomography scanning (HRCT) and bronchoscopy with lavage, was performed on the basis of well-defined clinical, radiological, and microbiological criteria. Only seropositive patients and patients with a positive microbiological test result plus supportive radiological findings received liposomal amphotericin B.


RESULTS
Neutropenic fever developed in 117 episodes, of which at least 41 episodes (35%) satisfied existing criteria for empirical antifungal therapy. However, our protocol-driven preemptive approach reduced the rate of antifungal use for these episodes from 35% to 7.7% (a 78% reduction) and led to the early initiation of antifungal therapy in 10 episodes (7.3%) that were clinically not suspected of being IFI. No undetected cases of invasive aspergillosis were identified; 1 case of zygomycosis was missed. Breakthrough candidemia was diagnosed by conventional culture techniques and was treated successfully. With use of a preemptive approach, the 12-week survival rate for patients with IFI was 63.6% (it was 63.1% for those with invasive aspergillosis).


CONCLUSIONS
Preemptive therapy based on enzyme immunoassay and HRCT reduced the exposure to expensive and potentially toxic drugs and offered effective antifungal control, but it failed to detect non-Aspergillus IFI.
Maertens
Johan
J
Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium. johan.maertens@uz.kuleuven.ac.be
Theunissen
Koen
K
Verhoef
Gregor
G
Verschakelen
Johnny
J
Lagrou
Katrien
K
Verbeken
Eric
E
Wilmer
Alexander
A
Verhaegen
Jan
J
Boogaerts
Marc
M
Van Eldere
Johan
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000465:Algorithms; D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000517:prevention & control; D005240:Feasibility Studies; D005260:Female; D005690:Galactose / Q000031:analogs & derivatives; D006801:Humans; D008172:Lung Diseases, Fungal / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000517:prevention & control; D008297:Male; D008351:Mannans / Q000097:blood*; D008875:Middle Aged; D009181:Mycoses / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000517:prevention & control*; D009503:Neutropenia / Q000150:complications*; D011446:Prospective Studies; D012307:Risk Factors; D014057:Tomography, X-Ray Computed
D000935:Antifungal Agents; D008351:Mannans; C012990:galactomannan; D000666:Amphotericin B; D005690:Galactose